The Harmonized PAT Solution:

Size: px
Start display at page:

Download "The Harmonized PAT Solution:"

Transcription

1 The Harmonized PAT Solution: Application of Risk-Based Tools & PAT Strategies in Pharmaceutical Product Manufacture Jeffrey A. Priem Cubist Pharmaceuticals

2 Presentation Objectives Provide Overview of FDA s PAT Initiative Provide Overview of Risk Management & Risk Assessment Tools Provide PAT Strategy for Pharma Industry Present Case Example on PAT Strategy Take Home Message PAT = Understanding + Risk Mitigation Page 2

3 PAT Elements Understanding Principles & Tools PAT Tools Multivariate Data Acquisition & Analysis tools Analyzers Control Systems Risk-Based Approach Integrated Systems Approach Real Time Release PAT A Framework for Innovative Pharmaceutical Development, Manufacturing, & Quality Assurance, Sept 2004 Page 3

4 PAT Challenges Technology Regulatory Driver Product Pipelines Automation Product Characterization Understanding, Variation, Specificity, Robustness, Technology, & Regulatory Uncertainty Page 4

5 Risk, Risk Assessments & Risk Management Page 5

6 Risk Assessment: Applications Risk Assessment Project Type Regulatory Proactive Situation Due Diligence GCP & GMP Assessment New Product (Beginning of Lifecycle) Risk Assessment Application Reactive Situation Crisis Management Regulatory Issues Complaints & Adverse Events Consent Decree & Warning Letter Product (Patient Focus) Drug Development Drug Development Remediation Re-Engineering (Middle of Development Lifecycle) Mature Risk Mitigation Financial Merger & Acquisition Feasibility Crisis Management Page 6

7 Quality System Applications & Risk Assessments Drug Development Change Control Acceptance Testing Product Traceability CAPA Purchasing Controls Production & Controls Root Cause Analysis Validation Complaints Environmental Control Design Page 7

8 text Risk Analysis Approaches Risk Matrixes Probability vs. Severity = High, Medium, or Low Risk Definition & Categorization Level I = Level II = Level III = Pre-Defined Question & Decision Tree If then, else Yes Occurrence Medium Risk Low Risk Do Control Measure(s) exist for the identified hazard? Yes No Does this step eliminate or reduce the likely occurrence of a hazard to an acceptable level? No Could the identified hazard(s) occur in excess of acceptable level(s) or could it increase to an unacceptable level(s)? Yes Will a subsequent step eliminate the identified hazard(s) or reduce its likely occurrence to an acceptable level? High Risk Severity Is control at this step necessary for Intended Use (SQUIPP)? Yes No Not A CCP Yes Modify Step, or Product No Critical Control Point Page 8

9 Risk Assessment Tools FMEA - Failure Modes Effects Analysis FMECA - Failure Modes Effects & Criticality Analysis FTA - Fault Tree Analysis HACCP - Hazard Analysis Critical Control Points And Combination Methods Tools & Approaches Page 9

10 Combination Methods Overview Key Questions to Ask & Understand What is the Risk Focus? What are the Risk Requirements? What are the Risk Metrics to be quantified & Measured? What is the Outcome of the Exposure? As well as What is it you need? How do you plan to do it? What is the ultimate outcome? What are the challenges? Balance RA Tools vs. RA Approaches Format Content Context Intent Implementation Integration Effectiveness Page 10

11 Risk Management: Applications Risk Assessment Categories (Project Type) Regulatory Proactive Situation Due Diligence GMP Assessment New Product (Beginning of Lifecycle) Risk Assessment Application Reactive Situation Crisis Management Regulatory Issues Consent Decree Warning Letter FDA-483 Product Product Development Design Control (Beginning of Lifecycle) Re-Engineering (Middle of Development Lifecycle) Design Control (Middle of Design Lifecycle or After Design) Mature Risk Mitigation Financial M&A Feasibility Crisis Management Page 11

12 Risk Management Concept ICH Q9: Quality Risk Management Risk Assessment Risk Analysis Risk Evaluation Risk Control ISO Risk Management Monitoring & Performance Measurement Risk Management Planning Page 12

13 The Harmonized PAT Solution Page 13

14 The Simplified Model Requirements Performance Regulators Organization Customer Metrics Measurement Monitoring Requirements DRIVE Performance Page 14

15 Understanding Concept: Variation People Materials Methods Input Output Environment Equipment Measurement Page 15

16 Harmonized PAT PAT Elements Risk Management PAT Tools Provide Risk Multivariate Data Based Decision Acquisition & Analysis es Tools Provide Modern Rationale on Analyzers / process where to apply analytical chemistry Technology tools Provide & Endpoint Framework to monitoring & control facilitate tools Understanding & Continuous Decision Making Improvement & KM Provide Understanding Framework to Risk-Based Approach execute Riskbased strategies Integrated Systems Approach Real Time Release PAT Strategy Understanding Analysis Identify critical attributes Identify automation attributes Identify monitoring & control elements Obtain Knowledge of product & process specifications & requirements Provide understanding of QS interfaces Analyze risk at product, process, & quality systems perspective Define Mitigation Strategy Optimization Implement test strategies Optimize Implement Optimization points Apply Technology Page 16

17 PAT Application Example Technology Transfer & Validation Page 17

18 Understanding Identify product requirements Define how they were derived Quantify robustness & adequacy Correlate Attributes to Interfaces System Component Specification Identification Map Flow Diagram Harmonized PAT Solution Activity Key Elements Identify Each Step Identify Elements for Variation: Equipment, Measurement, Personnel, Methods, Materials, Environment, Controls & Monitoring Flow Identify Step Outcome Map Key Inputs: Data / Information and Procedures / guidance Map Outputs & Deliverables Identify Quality System Interfaces, Performance Measures, & Milestones Page 18

19 Understanding Identification Deliverable Matrix of those Elements of Variation Page 19

20 & Filename: KM Doc Development PFD rdr0.vsd Workflow Key Inputs Data / Information Procedures / Guidance Services Provided / CS Group Established Documents / CS Group Index of Documents needed to support services Rationale to Drive Consensus Template Document Technical Content Documents (References) CS Group Input / Feedback on Technical Content Preliminary Draft Document Technical Content Documents (References) KMI Document / Tracking # Draft Document Technical Content Documents Approved Document KMI Document Management & Change Control Procedure Product and Planning Document Development Document Review Review & Approval Deployment PAREXEL / KMI Policies: Change Control Posting / Handling of knowledge asset Continuous Improvement KMI Document Review & Revision Plan Flow Diagram "Knowledge Document" Development & Responsibilities Determine Documents to be developed Determine Priority Determine Schedule / Milestones Determine Resource Obtain Responsible CS Group Approval Obtain KMI Exec Management Approval Key Outputs (Outputs from Step) CS Group Specific Service & Documents Matrix MD CA SC QS VC IT CS Group Approval Services Documents Resources Exec Mgmt Approval Resources Timelines Deliverables Quality System Interfaces or Performance Measures QS Interfaces: Personnel: KMI Executive Management CS Group Directors KMI Strategic Plan Resource Utilization / Planning Critical Success Factors: Understanding of concept & context of project by Exec Mgmt & CS Group Directors Obtain Buy-in from Exec Mgmt Obtain Buy-in from CS Group Directors Obtain Template QS Interfaces: Format Personnel: CS Group SME's KM for Templates & Technical Content Determine searches Technical Content BO - Administration for KMI Documents for Document - Reference Resources CS Group Consensus on Performance Measures: Solicit feedback Deliverable Conformance to approved scheduled Conformance to template standard Preliminary Draft & Develop Draft Critical Success Factors: Document Document Templates established to focus on Technical Content Issues Author Time to develop document Staying on track with development (Focused) Perform Internal Quality System Interfaces: CS Group Review CS Group "QA" Review & SMEs of Document BO - Administration (Document Review Edit's & Management Log-in) Perform "QA" Map Red-lines KM - Facilitate process review & technical content review Performance Measures: Conformance to approved scheduled Conformance to template standard Revise Conformance to Technical Content Draft reference materials & interpretation Document Forward document to KM Critical Success Factors: Reviewer time commitment Document Staying on track with schedule Log Document & Tracking & Log Accessibility of SME's in event tech Establish Tracking Entry content is not available / accessible Forward document to KMI Cross functional Review Board Perform review CS Grp Dir & KM KMI Exec Mgmt, CS Grp Dir & KM CS Grp Dir CS Grp Dir & SME's CS Grp Dir, Author, & SME's KM KM KMI Rev Tm KM Edits Required? Yes KM No Yes Transition for Implementation: Change Control Internal Training Deployment on Knowledgebase CS Grp Dir & Author Consider Comments CS Grp Dir Incorporate & Author recommended No changes No Provide rationale why changes not made Yes KMI (?) Document Approved? Review & Revisions KM Review Comments Justification / Rationale Approved Document Document Deliverable Training Materials Knowledgebase Access Quality System Interfaces: KMI Review Team - Cross-Functional Management Review Team (Principal / Senior Consultant) to review, provide feedback & approval KM - Facilitate process CS Group Author & Mgmt - process feedback Performance Measures: Conformance to approved scheduled Conformance to Technical Content reference materials & interpretation Critical Success Factors: Reviewer time commitment Accessibility of Reviewers Staying on track with schedule Accessibility of SME's in event tech content is not available / accessible Focused Reviewers Reviews (Mitigating the propensity to word smith & redesign document) Quality System Interfaces: BO - Administration (Document Management) EO - Internal Training - Website Quality System Interfaces: BO - Administration (Document Change Control) CS Group's - Review & Revision KM - Facilitate Performance Measures & CSF's: To be determined Outcomes Obtain consensus on services that each CS Group provides, documents needed to support services, and resources required to support the development of those documents Obtain Approval to proceed for: Personnel Commitments Timelines Deliverables Deliverables format Established Draft document which satisfies CS Group Service needs Document developed conforms to select industry standards & KMI has established position on how KMI conforms to such requirements Obtain CS Group Consensus on approach and deliverable Capture draft document (something is better than nothing) Obtain collective KMI Technical Review on document & components presented (Consensus & Agreement) Approved, controlled, deployed & trained document Implement KMI Document Review & Revision es to KMI Knowledge Documents 2002 KMI, a division of PAREXEL International, LLC KMI, a division of PAREXEL International LLC, (KMI) considers this document to be confidential & for the sole use of KMI. All rights reserved. No part of this document may be reproduced or transmitted in any form, by any means (electronic, photocopying, recording, or otherwise) with written permission of KMI Specifications Procedures Materials Equipment / Systems Environment Measurement Personnel Map Workflow Flow diagram of processes & activities Outcome Per each level Key Inputs Date & Information into the Procedures & Guidance that Drive Key Outputs Deliverables Result for Activities Result from Quality System Interfaces Quality Program Linkage Points Performance Measurement Metrics to measure performance Page 20

21 Analysis Define Product Risks Identify Risks Identify Quality System Risk Areas Correlate Risks to Mitigation Strategies Page 21

22 Analysis Risk Assessment Fault Tree Analysis Tree Example Failure of Sterility Fermentation Sampling QC Test Equip 1149 Failure QC Test Eq 1149 out of Calibration Page 22

23 Analysis HACCP Deliverables Hazard Identification Hazard Analysis Critical Control Points HACCP Plan Level of Detail & Effort Time Focus is on those Critical Elements of the! Page 23

24 Analysis Quality System Risk Quantification PDA Scale Boston Low: December, 0 to Medium: 4.0 to 7.9 High: 8.0 to 10 Page 24

25 Optimization Define Analysis Areas Implement Corrective Action Plan Execute Optimization Strategies Implement Technology & Solutions Page 25

26 Deviation Management MFG Flow Diagram & Map Deviation Management No Forward approved change to implementation team leader Create a Change Implementation Plan If appropriate, establish a method for determining the effectiveness of the change Is the Change Implementation Plan approved? Yes Proceed with plan and provide progress updates according to schedule Prepare for senior management periodic summary reports. Complete Change Implementation Plan Submit documentation of completed implementation to Change Control Manager Has implementation been completed? Yes Is change effectiveness monitoring required? Yes Collect & evaluate effectiveness data Was change effective? Yes Submit CRF to CCM for MCF closure Close MCF MFG End No No No Change Control Out of Specifications Cross-Functional Implications Out of Specifications Systems-Based Model & Top-Down Approach Integrated Quality Systems Pre-Planned Linkages for Risk Management & Performance Measurement MFG Change Control Page 26

27 Implementation Measure Control & Monitor Analyze Review Refine Revise Again Requirements DRIVE Performance Page 27

28 Risk Management Define Scope Approach Interfaces Outcome Page 28

29 Risk Management & Drug Development Lifecycle Product Lifecycle: Discovery Development Manufacturing Distribution Basic Research Pre-Clinical Clinical I II III III B IV Product Launch Production Marketing and Sales Bottoms-Up Approach Risk Management & Drug Development Page 29

30 Risk Management & Drug Development Lifecycle Product Lifecycle: Discovery Development Manufacturing Distribution Basic Research Pre-Clinical Clinical I II III III B IV Product Launch Production Marketing and Sales Top Down Approach Risk Management & Product Lifecycle Page 30

31 Risk Management System Inputs Observation Records & Preliminary Investigation Formal Investigation & Action Identification Action Implementation Action Database & Follow-up Protocol Failure: Validation, Stability, Action Implementation OOS Results Deviations From Procedure Clinical Study Failures Complaints Adverse Events Audit Observations Deviation Mgmt / NCMR Data observed of Exception Preliminary evaluation & Investigation CAPA Adverse Trends in data Data exceptions Preliminary evaluation & Investigation Level II / III Action analysis team review for level III & optional Level II Review Formal Investigation, action identification & authorization for Level II/III Results Regulatory Review for Level III & Optional Level II Review Level I Level II/III Level II Action implementation Planning Protocol Creation & Implementation Level II/III Action Database Audits Effectiveness Assessment Follow-up Product Design Level I N... Page 31 Reference: "Risk Management Basics", DeSain, Vercimak, Sutton

32 Risk Management System Inputs Observation Records & Preliminary Investigation Formal Investigation & Action Identification Action Implementation Action Database & Follow-up Protocol Failure: Validation, Stability, Action Implementation OOS Results Deviations From Procedure Clinical Study Failures Complaints Adverse Events Audit Observations Deviation Mgmt / NCMR Data observed of Exception Preliminary evaluation & Investigation CAPA Adverse Trends in data Data exceptions Preliminary evaluation & Investigation Level II / III Action analysis team review for level III & optional Level II Review Formal Investigation, action identification & authorization for Level II/III Results Regulatory Review for Level III & Optional Level II Review Level I Level II/III Level II Action implementation Planning Protocol Creation & Implementation Level II/III Action Database Audits Effectiveness Assessment Follow-up Product Design Level I N... Page 32 Reference: "Risk Management Basics", DeSain, Vercimak, Sutton

33 Outcomes Page 33

34 PAT Application Project Outcomes Improved Product Quality Optimization of es & Interfaces Reduction in Production Cycle Time Variation Mitigation Epiphany: The Ah Ha! Factor Cost Savings & Optimized Resources Technology Personnel ROI Defendable Compliance vs. Minimal Compliance Page 34

35 The Harmonized PAT Solution: Application of Risk-Based Tools & PAT Strategies in Pharmaceutical Product Manufacture By: Jeff Priem Tel:

QUALITY RISK MANAGEMENT (QRM): A REVIEW

QUALITY RISK MANAGEMENT (QRM): A REVIEW Lotlikar et al Journal of Drug Delivery & Therapeutics; 2013, 3(2), 149-154 149 Available online at http://jddtonline.info REVIEW ARTICLE QUALITY RISK MANAGEMENT (QRM): A REVIEW Lotlikar MV Head Corporate

More information

Best Practice In A Change Management System

Best Practice In A Change Management System Quality & Compliance Associates, LLC Best Practice In A Change Management System President Quality & Compliance Associates, LLC Change Control and Its Role in a Continuous Improvement Environment 3 Benefits

More information

Addressing Risk in Partner / Contractor Selection and Onboarding. Michael Davidson VP Quality Systems and Compliance March 2014

Addressing Risk in Partner / Contractor Selection and Onboarding. Michael Davidson VP Quality Systems and Compliance March 2014 Addressing Risk in Partner / Contractor Selection and Onboarding Michael Davidson VP Quality Systems and Compliance March 2014 Industry Trends Pfizer Overview Pfizer s Approach Risk Based Robust Due Diligence

More information

Application of Quality Risk Management to Pharmaceutical Operations. Eldon Henson, Vice President, Quality Operations

Application of Quality Risk Management to Pharmaceutical Operations. Eldon Henson, Vice President, Quality Operations Application of Quality Risk Management to Pharmaceutical Operations Eldon Henson, Vice President, Quality Operations Key Topics of Discussion Definition of Quality Risk Management (QRM) Overview of PDA

More information

Quality Risk Management

Quality Risk Management PS/INF 1/2010 * * Quality Risk Management Quality Risk Management Implementation of ICH Q9 in the pharmaceutical field an example of methodology from PIC/S Document > Authors: L. Viornery (AFSSAPS) Ph.

More information

ICH Q10 - Pharmaceutical Quality System

ICH Q10 - Pharmaceutical Quality System WCC PDA Dinner Meeting Jan 2012 ICH Q10 - Pharmaceutical Quality System Neil Wilkinson NSF-DBA www.nsf-dba.com ICHQ10.1 WCC PDA Dinner Meeting Jan 2012 Your Presenter Partner at NSF-DBA USA Training, Consultancy,

More information

Quality Risk Management ICH Q9 & ISO 14971. Presented by Michael Kerr 11 th November 2011

Quality Risk Management ICH Q9 & ISO 14971. Presented by Michael Kerr 11 th November 2011 Quality Risk Management ICH Q9 & ISO 14971 Presented by Michael Kerr 11 th November 2011 Agenda Risk Concept QRM Fundamentals Regulatory Expectations Warning Letters / Observations Application of QRM Introduction:

More information

Guidance for Industry. Q10 Pharmaceutical Quality System

Guidance for Industry. Q10 Pharmaceutical Quality System Guidance for Industry Q10 Pharmaceutical Quality System U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation

More information

Quality Risk Management - The Medical Device Experience. Niamh Nolan Principal Design Assurance Engineer Boston Scientific

Quality Risk Management - The Medical Device Experience. Niamh Nolan Principal Design Assurance Engineer Boston Scientific Quality Risk Management - The Medical Device Experience Niamh Nolan Principal Design Assurance Engineer Boston Scientific Agenda Intent of Risk Management (RM) and Associated Regulations Overview of RM

More information

Quality Risk Management Tools Quality Risk Management Tool Selection When to Select FMEA: QRM Tool Selection Matrix

Quality Risk Management Tools Quality Risk Management Tool Selection When to Select FMEA: QRM Tool Selection Matrix Quality Risk Management Tools Quality Risk Management Tool Selection When to Select FMEA: QRM Tool Selection Matrix 26 Quality Risk Management Tools The ICH Q9 guideline, Quality Risk Management, provides

More information

Barnett International and CHI's Inaugural Clinical Trial Oversight Summit June 4-7, 2012 Omni Parker House Boston, MA

Barnett International and CHI's Inaugural Clinical Trial Oversight Summit June 4-7, 2012 Omni Parker House Boston, MA Barnett International and CHI's Inaugural Clinical Trial Oversight Summit June 4-7, 2012 Omni Parker House Boston, MA This presentation is the property of DynPort Vaccine Company LLC, a CSC company, and

More information

TrackWise - Quality Management System

TrackWise - Quality Management System TrackWise - Quality Management System Focus area: Electronic Management of CAPA Systems in the Regulated Industry May 11, 2007 Yaniv Vardi VP, Operations Sparta Systems Europe, Ltd. Agenda Sparta Systems

More information

Corrective and Preventive Action Background & Examples Presented by:

Corrective and Preventive Action Background & Examples Presented by: Corrective and Preventive Action Background & Examples Presented by: Kimberly Lewandowski-Walker Food and Drug Administration Division of Domestic Field Investigations Office of Regulatory Affairs Overview

More information

Enterprise Level Change Control: A Life Science Business Imperative. Presented by: Carl Ning Solutions Delivery Manager Sparta Systems

Enterprise Level Change Control: A Life Science Business Imperative. Presented by: Carl Ning Solutions Delivery Manager Sparta Systems Enterprise Level Change Control: A Life Science Business Imperative Presented by: Carl Ning Solutions Delivery Manager Sparta Systems Agenda Global Change Control: An Overview Benefits and Challenges Change

More information

Process Validation: Practical Aspects of the New FDA Guidance

Process Validation: Practical Aspects of the New FDA Guidance Process Validation: Practical Aspects of the New FDA Guidance ISPE Boston Chapter Meeting April 18, 2013 Rusty Morrison Commissioning Agents, Inc. Objectives / Summary What is Process Validation? Regulatory

More information

Optimizing Quality Control / Quality Assurance Agents of a Global Sourcing / Procurement Strategy

Optimizing Quality Control / Quality Assurance Agents of a Global Sourcing / Procurement Strategy Optimizing Quality Control / Quality Assurance Agents of a Global Sourcing / Procurement Strategy Global Pharma Sourcing Conference December 6-7, 2011 Philadelphia, USA Nigel J. Smart, Ph.D. Smart Consulting

More information

Quality Risk Management The Pharmaceutical Experience Ann O Mahony Quality Assurance Specialist Pfizer Biotech Grange Castle

Quality Risk Management The Pharmaceutical Experience Ann O Mahony Quality Assurance Specialist Pfizer Biotech Grange Castle Quality Risk Management 11 November 2011 Galway, Ireland Quality Risk Management The Pharmaceutical Experience Ann O Mahony Quality Assurance Specialist Pfizer Biotech Grange Castle Overview Regulatory

More information

Imperative. Tim Mohn Industry Principal Sparta Systems

Imperative. Tim Mohn Industry Principal Sparta Systems Enterprise Level ChangeControl: Control: A Life Science Business Imperative Tim Mohn Industry Principal Sparta Systems Agenda GlobalChange Control: An Overview Benefits and Challenges Change Control as

More information

Quality Risk Management Principles and Industry Case Studies

Quality Risk Management Principles and Industry Case Studies Final Draft Rev. December 28, 2008 Quality Risk Management Principles and Industry Case Studies T. Frank 1, S. Brooks 2, R. Creekmore 3, B. Hasselbalch 4, K. Murray 5, K. Obeng 6, S. Reich 5, E. Sanchez

More information

ICH Public Meeting. Joseph C. Famulare. October 2, 2006. Acting Deputy Director Office of Compliance CDER / FDA Office of Compliance

ICH Public Meeting. Joseph C. Famulare. October 2, 2006. Acting Deputy Director Office of Compliance CDER / FDA Office of Compliance ICH Public Meeting October 2, 2006 Joseph C. Famulare Acting Deputy Director Office of Compliance CDER / FDA Office of Compliance The Current State of Pharmaceutical Manufacturing Inability to predict

More information

Edwin Lindsay Principal Consultant. Compliance Solutions (Life Sciences) Ltd, Tel: + 44 (0) 7917134922 E-Mail: elindsay@blueyonder.co.

Edwin Lindsay Principal Consultant. Compliance Solutions (Life Sciences) Ltd, Tel: + 44 (0) 7917134922 E-Mail: elindsay@blueyonder.co. Edwin Lindsay Principal Consultant, Tel: + 44 (0) 7917134922 E-Mail: elindsay@blueyonder.co.uk There were no guidelines/ regulations There was no training No Procedures No Inspectors Inform All staff of

More information

Pharmaceutical Quality Systems: US Perspective

Pharmaceutical Quality Systems: US Perspective Pharmaceutical Quality Systems: US Perspective Rick Friedman Associate Director, Office of Manufacturing and Product Quality Center for Drug Evaluation and Research Topics Background: The ICH Q10 Pharmaceutical

More information

PHARMACEUTICAL QUALITY SYSTEM Q10

PHARMACEUTICAL QUALITY SYSTEM Q10 INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE PHARMACEUTICAL QUALITY SYSTEM Q10 Current Step

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Q9 Quality Risk Management U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation

More information

Risk Assessment and Management. Allen L. Burgenson Manager, Regulatory Affairs Lonza Walkersville Inc.

Risk Assessment and Management. Allen L. Burgenson Manager, Regulatory Affairs Lonza Walkersville Inc. Risk Assessment and Management Allen L. Burgenson Manager, Regulatory Affairs Lonza Walkersville Inc. Standard Disclaimer Standard Disclaimer: This presentation is the opinion of the presenter, and does

More information

Risk assessment is used as a

Risk assessment is used as a FOCUS ON... COMPLIANCE Author Insights Online Exclusive www.bioprocessintl.com/bpiextra Quality Risk Management for Drug Products and Drug Substances by Thomas A. Little Risk assessment is used as a vetting

More information

Quality Risk Management Understanding and Control the Risk in Pharmaceutical Manufacturing Industry

Quality Risk Management Understanding and Control the Risk in Pharmaceutical Manufacturing Industry International Journal of Pharmaceutical Science Invention ISSN (Online): 2319 6718, ISSN (Print): 2319 670X Volume 4 Issue 1 January 2015 PP.29-41 Quality Risk Management Understanding and Control the

More information

Improved Utilization of Self-Inspection Programs within the GMP Environment A Quality Risk Management Approach

Improved Utilization of Self-Inspection Programs within the GMP Environment A Quality Risk Management Approach Improved Utilization of Self-Inspection Programs within the GMP Environment A Quality Risk Management Approach Barbara Jeroncic Self-inspection is a well-established and vital part of the pharmaceutical

More information

Quality by Design (QbD) Overview

Quality by Design (QbD) Overview Quality by Design (QbD) Overview Gary Warren Director, Haemostasis and Thrombosis R&D October, 2015 CSL Behring Pty Ltd Broadmeadows, Victoria What is Quality by Design (QbD)? QbD is: A Quality System

More information

Product Quality Management

Product Quality Management Product Quality Management Deborah Baly, Ph.D Sr. Director, Commercial Product Quality Management, GNE/ROCHE 1 Presentation Outline: Product Quality Management Regulatory landscape and need for integrated

More information

Quality Risk Management in Pharmaceutical Industry: A Review

Quality Risk Management in Pharmaceutical Industry: A Review International Journal of PharmTech Research CODEN (USA): IJPRIF ISSN : 0974-4304 Vol.6, No.3, pp 908-914, July-Aug 2014 Quality Risk Management in Pharmaceutical Industry: A Review V Vijayakumar Reddy*,

More information

Annex 2. WHO guidelines on quality risk management. 1. Introduction 62. 2. Glossary 67 3. Quality risk management process 70

Annex 2. WHO guidelines on quality risk management. 1. Introduction 62. 2. Glossary 67 3. Quality risk management process 70 Annex 2 WHO guidelines on quality risk management 1. Introduction 62 1.1 Background and scope 62 1.2 Principles of quality risk management 64 2. Glossary 67 3. Quality risk management process 70 3.1 Initiating

More information

Let s skip over the next ten

Let s skip over the next ten FOCUS ON... COMPLIANCE Risk-Based Quality Management Systems What Are We Waiting For? by Carol DeSain Let s skip over the next ten years, the changes in FDA policy, politics and leadership; the age-old

More information

Mapping Your Success Top Non-Conformities Requiring a CAPA Process

Mapping Your Success Top Non-Conformities Requiring a CAPA Process Mapping Your Success Top Non-Conformities Requiring a CAPA Process Agenda FDA Statistics for 2012 BSI Statistics for 2012 EQMS industry benchmark data About CAPA Traits of Software Solution for CAPA 2

More information

FDA Software Validation-Answers to the Top Five Software Validation Questions

FDA Software Validation-Answers to the Top Five Software Validation Questions Whitepaper FDA Software Validation-Answers to the Top Five Software Validation Questions Author: Penny Goss, Penny Goss Technical Solutions The FDA (Food and Drug Administration) and IEC (International

More information

With the introduction of GAMP 5, A

With the introduction of GAMP 5, A Online Exclusive from PHARMACEUTICAL ENGINEERING The Official Magazine of ISPE January/February 2012, Vol. 32 No. 1 www.pharmaceuticalengineering.org Copyright ISPE 2012 This article presents the case

More information

Impact Assessment in a Science & Risk Based Environment. R. Legland 11/04/11

Impact Assessment in a Science & Risk Based Environment. R. Legland 11/04/11 Impact Assessment in a Science & Risk Based Environment R. Legland 11/04/11 Background US GMP s EU GMP s Japan GMP s ICH Q8, Q9, Q10 Guidance ASTM Standard E2500-07 Science and Risk Based Approach to Determine

More information

QUALITY RISK MANAGEMENT

QUALITY RISK MANAGEMENT INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE QUALITY RISK MANAGEMENT Q9 Current Step 4 version

More information

ICH Q10 Pharmaceutical Quality System (PQS)

ICH Q10 Pharmaceutical Quality System (PQS) ICH Q10 Pharmaceutical Quality System (PQS) International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use ICH Q10 PQS Guideline Background Objectives

More information

Overview of EAM Services. A Fully Integrated Global EAM Service Provider

Overview of EAM Services. A Fully Integrated Global EAM Service Provider A Fully Integrated Global EAM Service Provider Table of Contents Strategy & Process Services Overview... p. 3 Asset Reliability Services Overview... p. 4 Systems & Technology Services Overview... p. 7

More information

International GMP Requirements for Quality Control Laboratories and Recomendations for Implementation

International GMP Requirements for Quality Control Laboratories and Recomendations for Implementation International GMP Requirements for Quality Control Laboratories and Recomendations for Implementation Ludwig Huber, Ph.D. ludwig_huber@labcompliance.com Overview GMP requirements for Quality Control laboratories

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Q8, Q9, and Q10 Questions and Answers(R4) U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics

More information

Conducting a Gap Analysis on your Change Control System. Presented By Miguel Montalvo, President, Expert Validation Consulting, Inc.

Conducting a Gap Analysis on your Change Control System. Presented By Miguel Montalvo, President, Expert Validation Consulting, Inc. Conducting a Gap Analysis on your Change Control System Presented By Miguel Montalvo, President, Expert Validation Consulting, Inc. Standards, Regulations, Guidelines related to Change Control Management

More information

Guidance for Industry: Quality Risk Management

Guidance for Industry: Quality Risk Management Guidance for Industry: Quality Risk Management Version 1.0 Drug Office Department of Health Contents 1. Introduction... 3 2. Purpose of this document... 3 3. Scope... 3 4. What is risk?... 4 5. Integrating

More information

Operational Excellence for Data Quality

Operational Excellence for Data Quality Operational Excellence for Data Quality Building a platform for operational excellence to support data quality. 1 Background & Premise The concept for an operational platform to ensure Data Quality is

More information

PROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7: NON-STERILE PROCESS VALIDATION

PROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7: NON-STERILE PROCESS VALIDATION April 2013 RESTRICTED 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 PROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES:

More information

Hazard Analysis and Critical Control Points (HACCP) 1 Overview

Hazard Analysis and Critical Control Points (HACCP) 1 Overview Manufacturing Technology Committee Risk Management Working Group Risk Management Training Guides Hazard Analysis and Critical Control Points (HACCP) 1 Overview Hazard Analysis and Critical Control Point

More information

ORACLE CONSULTING GROUP

ORACLE CONSULTING GROUP ORACLE CONSULTING GROUP 9 Golder Ranch Rd., Ste. 1 Tucson, Arizona 9 Web Site: E-mail: 20-2-0 20-2-0 (FAX) CONSULTING MEMORANDUM QUALITY SYSTEM INSPECTION TECHNIQUE

More information

ICH guideline Q10 on pharmaceutical quality system

ICH guideline Q10 on pharmaceutical quality system September 2015 EMA/CHMP/ICH/214732/2007 Committee for Human Medicinal Products Step 5 Transmission to CHMP May 2007 Transmission to interested parties May 2007 Deadline for comments November 2007 Final

More information

Standard of measurement by which efficiency, performance, progress, or quality of a plan, process, or product can be assessed 1.

Standard of measurement by which efficiency, performance, progress, or quality of a plan, process, or product can be assessed 1. Meaningful Metrics What is a Metric? Standard of measurement by which efficiency, performance, progress, or quality of a plan, process, or product can be assessed 1. A quality metric is a measurement of

More information

How to Use the Design Process to Manage Risk: Elements of Design Controls and Why It Matters

How to Use the Design Process to Manage Risk: Elements of Design Controls and Why It Matters environmental failure analysis & prevention health technology development How to Use the Design Process to Manage Risk: Elements of Design Controls and Why It Matters Kevin L. Ong, Ph.D., P.E. Managing

More information

ISO 14971: Overview of the standard

ISO 14971: Overview of the standard FDA Medical Device Industry Coalition ISO 14971: Overview of the standard Risk Management Through Product Life Cycle: An Educational Forum William A. Hyman Department of Biomedical Engineering Texas A&M

More information

Risk Management Services

Risk Management Services Risk Management Services GridSME is proud to offer organizations a variety of risk management services, including the following: RISK ASSESSMENTS Strategic identification of enterprise risks & latent organizational

More information

Guidance for Industry Quality Systems Approach to Pharmaceutical CGMP Regulations

Guidance for Industry Quality Systems Approach to Pharmaceutical CGMP Regulations Guidance for Industry Quality Systems Approach to Pharmaceutical CGMP Regulations U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)

More information

ASSESSMENT OF QUALITY RISK MANAGEMENT IMPLEMENTATION

ASSESSMENT OF QUALITY RISK MANAGEMENT IMPLEMENTATION PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PI 038-1 26 March 2012 AIDE-MEMOIRE ASSESSMENT OF QUALITY RISK MANAGEMENT IMPLEMENTATION PIC/S March 2012 Reproduction

More information

EMA Clinical Laboratory Guidance - Key points and Clarifications PAUL STEWART

EMA Clinical Laboratory Guidance - Key points and Clarifications PAUL STEWART EMA Clinical Laboratory Guidance - Key points and Clarifications PAUL STEWART Framework Labs generate data that are used to make decisions on the safety and efficacy of medicinal products; consequently,

More information

200Canada Bridges Page 1 07/11/2009. Project Management: Trainee Guide Module 1 INTRODUCTION

200Canada Bridges Page 1 07/11/2009. Project Management: Trainee Guide Module 1 INTRODUCTION 200Canada Bridges Page 1 07/11/2009 Project Management: Trainee Guide Module 1 INTRODUCTION Bridges Social Development Project Management Training Program www.canadabridges.com http://training.canadabridges.com/

More information

The Effective Management of Change Across the ICHQ10 Lifecycle

The Effective Management of Change Across the ICHQ10 Lifecycle The Effective Management of Change Across the ICHQ10 Lifecycle Rob Hughes AstraZeneca 1 Change Management the guide This presentation will: describe a structured approach to change across the ICH Q10 lifecycle

More information

ISO 22000 Food Safety Management System

ISO 22000 Food Safety Management System This is an ideal package for Food Manufacturers looking to meet International Food Safety Standards. This system meets the requirements of International Standard ISO 22000:2005 for Food Safety Management

More information

ICH guideline Q8, Q9 and Q10 - questions and answers volume 4

ICH guideline Q8, Q9 and Q10 - questions and answers volume 4 December 2010 EMA/CHMP/ICH/265145/ Committee for medicinal products for human use (CHMP) ICH guideline Q8, Q9 and Q10 - questions and answers volume 4 Step 5 Transmission to CHMP for information December

More information

Media fills Periodic performance qualification (Re-Validation)

Media fills Periodic performance qualification (Re-Validation) Media fills Periodic performance qualification (Re-Validation) Minimum number of Simulations Number of units Contaminated Units Action a Two per Year (Retrospective & Prospective Validation) < 5000 5000

More information

Pharmaceutical Quality Management System: Current Concept

Pharmaceutical Quality Management System: Current Concept Pharmaceutical Quality Management System: Current Concept Neetu Dubey 1, *, Himanshu Gupta 3, R.K. Sharma 2, Nitin Dubey 1, Nidhi Dubey 4 1. IPS Academy, Indore, Madhya Pradesh, India. 2. Prestige Institute

More information

Commercial Manufacturing - Qualification & Validation-related GMP Deficiencies and Other Lifecycle Considerations

Commercial Manufacturing - Qualification & Validation-related GMP Deficiencies and Other Lifecycle Considerations Commercial Manufacturing - Qualification & Validation-related GMP Deficiencies and Other Lifecycle Considerations Kevin O Donnell PhD Market Compliance Manager, IMB PDA / FDA Conference Pharmaceutical

More information

Regulatory Asset Management: Harmonizing Calibration, Maintenance & Validation Systems

Regulatory Asset Management: Harmonizing Calibration, Maintenance & Validation Systems Regulatory Asset Management: Harmonizing Calibration, Maintenance & Validation Systems 800.982.2388 1 Introduction Calibration, maintenance and validation activity, despite operating within the same department

More information

ISO 9001: 2015 EXPECTATIONS OVERVIEW & Presenter Name Paul J. Kunder. Former US Representative to ISO 20 Yrs. Voting Member USTAG - TC 176

ISO 9001: 2015 EXPECTATIONS OVERVIEW & Presenter Name Paul J. Kunder. Former US Representative to ISO 20 Yrs. Voting Member USTAG - TC 176 OVERVIEW & EXPECTATIONS Presenter Name Paul J. Kunder Former US Representative to ISO 20 Yrs. Voting Member USTAG - TC 176 Purpose Of Presentation To provide an overview 9000:2015 9001:2015 Estimated Release

More information

QUALITY MANAGEMENT SYSTEM (QMS) ASSESSMENT CHECKLIST

QUALITY MANAGEMENT SYSTEM (QMS) ASSESSMENT CHECKLIST 1. QUALITY MANAGEMENT SYSTEM QUALITY MANAGEMENT SYSTEM (QMS) ASSESSMENT CHECKLIST 1.1 Quality Management System General 1.1.1 Is objective evidence available to demonstrate that the MDSAP site has defined,

More information

Welcome to the training on the TransCelerate approach to Risk-Based Monitoring. This course will take you through five modules of information to

Welcome to the training on the TransCelerate approach to Risk-Based Monitoring. This course will take you through five modules of information to Welcome to the training on the TransCelerate approach to Risk-Based Monitoring. This course will take you through five modules of information to introduce you to the concepts behind risk-based monitoring,

More information

Quality Assurance. Disclosure for Lilli Møller Andersen. No relevant financial relationships exist for any issue mentioned in this presentation

Quality Assurance. Disclosure for Lilli Møller Andersen. No relevant financial relationships exist for any issue mentioned in this presentation Quality Assurance Disclosure for Lilli Møller Andersen No relevant financial relationships exist for any issue mentioned in this presentation Agenda Quality Assurance Quality Management System Quality

More information

Software Development for Medical Devices

Software Development for Medical Devices Overcoming the Challenges of Compliance, Quality and Cost An MKS White Paper Introduction Software is fast becoming the differentiator for manufacturers of medical devices. The rewards available from software

More information

How Industry Can Partner with FDA in Defining a Risk- Based Monitoring Program

How Industry Can Partner with FDA in Defining a Risk- Based Monitoring Program How Industry Can Partner with FDA in Defining a Risk- Based Monitoring Program Presenter: Jan Holladay Pierre, MPH Quality Principal Leader DynPort Vaccine Company LLC, A CSC Company This presentation

More information

State of Medical Device Development. 2014 State of Medical Device Development seapine.com 1

State of Medical Device Development. 2014 State of Medical Device Development seapine.com 1 State of Medical Device Development 2014 2014 State of Medical Device Development seapine.com 1 Executive Summary The demand for smarter, safer, more connected medical devices has introduced new complexities

More information

Risk Assessment of Outsourcing Pharmaceutical Packaging

Risk Assessment of Outsourcing Pharmaceutical Packaging Risk Assessment of Outsourcing Pharmaceutical Packaging Dr Afshin Hosseiny November 2004 Slide Number 1 11/04 Why Outsource? Technical requirements Capacity requirements Speed of Setting up Location -

More information

Process Performance Qualification. Demonstrating a High Degree of Assurance in Stage 2 of the Process Validation Lifecycle

Process Performance Qualification. Demonstrating a High Degree of Assurance in Stage 2 of the Process Validation Lifecycle Process Performance Qualification Demonstrating a High Degree of Assurance in Stage 2 of the Process Validation Lifecycle A LIFECYCLE Approach to Process Validation? Lifecycle [ICH Q8(R2)]: All phases

More information

Aligning Quality Management Processes to Compliance Goals

Aligning Quality Management Processes to Compliance Goals Aligning Quality Management Processes to Compliance Goals MetricStream.com Smart Consulting Group Joint Webinar February 23 rd 2012 Nigel J. Smart, Ph.D. Smart Consulting Group 20 E. Market Street West

More information

Design Verification The Case for Verification, Not Validation

Design Verification The Case for Verification, Not Validation Overview: The FDA requires medical device companies to verify that all the design outputs meet the design inputs. The FDA also requires that the final medical device must be validated to the user needs.

More information

Testing Automated Manufacturing Processes

Testing Automated Manufacturing Processes Testing Automated Manufacturing Processes (PLC based architecture) 1 ❶ Introduction. ❷ Regulations. ❸ CSV Automated Manufacturing Systems. ❹ PLCs Validation Methodology / Approach. ❺ Testing. ❻ Controls

More information

Quality System: Design Control Procedure - Appendix

Quality System: Design Control Procedure - Appendix Quality System: Design Control Procedure - Appendix Page 1 of 10 Quality System: Design Control Procedure - Appendix CORP Medical Products Various details have been removed, indicated by [ ] 1. Overview

More information

Corrective and Preventive Actions

Corrective and Preventive Actions Corrective and Preventive Actions A Five Step Approach Topics to Be Covered What is CAPA? Governing authority Five steps to a good CAPA process Where companies have difficulty Example citations Recap What

More information

White paper. Corrective action: The closed-loop system

White paper. Corrective action: The closed-loop system White paper Corrective action: The closed-loop system Contents Summary How corrective action works The steps 1 - Identify non-conformities - Opening a corrective action 6 - Responding to a corrective action

More information

Innovative Solutions Designed to Improve Operational Capacity, Efficiency and Effectiveness in Clinical Monitoring

Innovative Solutions Designed to Improve Operational Capacity, Efficiency and Effectiveness in Clinical Monitoring Innovative Solutions Designed to Improve Operational Capacity, Efficiency and Effectiveness in Clinical Monitoring Brett Barber, Sr. Director, Strategic Resourcing Nicole Baker, Sr. Director, Strategic

More information

COMPLIANCE BY DESIGN FOR PHARMACEUTICAL QUALITY CONTROL LABORATORIES INSIGHT FROM FDA WARNING LETTERS

COMPLIANCE BY DESIGN FOR PHARMACEUTICAL QUALITY CONTROL LABORATORIES INSIGHT FROM FDA WARNING LETTERS COMPLIANCE BY DESIGN FOR PHARMACEUTICAL QUALITY CONTROL LABORATORIES INSIGHT FROM FDA WARNING LETTERS Primer CONTENTS INTRODUCTION...3 QUALITY AND COMPLIANCE IN QUALITY CONTROL LABORATORIES...5 Compliance

More information

Quality by Design Approaches to Analytical Methods -- FDA Perspective. Yubing Tang, Ph.D. FDA/CDER/ONDQA AAPS, Washington DC October 25, 2011

Quality by Design Approaches to Analytical Methods -- FDA Perspective. Yubing Tang, Ph.D. FDA/CDER/ONDQA AAPS, Washington DC October 25, 2011 Quality by Design Approaches to Analytical Methods -- FDA Perspective Yubing Tang, Ph.D. FDA/CDER/ONDQA AAPS, Washington DC October 25, 2011 1 Outline What is Quality by Design (QbD) Role of Analytical

More information

ComplianceSP TM on SharePoint. Complete Document & Process Management for Life Sciences on SharePoint 2010 & 2013

ComplianceSP TM on SharePoint. Complete Document & Process Management for Life Sciences on SharePoint 2010 & 2013 TM ComplianceSP TM on SharePoint Complete Document & Process Management for Life Sciences on SharePoint 2010 & 2013 Overview With increasing pressure on costs and margins across Life Sciences, the industry

More information

Harmonizing Change Control Processes Globally

Harmonizing Change Control Processes Globally Quality & Compliance Associates, LLC Harmonizing Change Control Processes Globally President Quality & Compliance Associates, LLC When We Deal In A Global Environment, How Do We Design A System That Addresses

More information

Gap Analysis of the Change Control Process The History of a Transformed Change Control System

Gap Analysis of the Change Control Process The History of a Transformed Change Control System Gap Analysis of the Change Control Process The History of a Transformed Change Control System Juan Alcazar Quality Systems Carolina, PR Content Introduction Gap Analysis Phases to perform a Gap Analysis

More information

GxP Process Management Software. White Paper: Ten Most Common Reasons for FDA 483 Observations and Warning Letter Citations

GxP Process Management Software. White Paper: Ten Most Common Reasons for FDA 483 Observations and Warning Letter Citations GxP Process Management Software : Ten Most Common Reasons for FDA 483 Observations and Warning Letter Citations Most FDA violations involve one of the following: Not having procedures in a regulated area

More information

The Paperless QMS March 2012

The Paperless QMS March 2012 The Paperless QMS March 2012 Overview Introductions What do we mean by Paperless QMS? Short history of the (pharma) Paperless QMS What do you need your Paperless QMS to do? Practical application and considerations

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Process Validation: General Principles and Practices U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center

More information

INTEGRATED MANAGEMENT SYSTEM MANUAL IMS. Based on ISO 9001:2008 and ISO 14001:2004 Standards

INTEGRATED MANAGEMENT SYSTEM MANUAL IMS. Based on ISO 9001:2008 and ISO 14001:2004 Standards INTEGRATED MANAGEMENT SYSTEM MANUAL IMS Based on ISO 9001:2008 and ISO 14001:2004 Standards Approved by Robert Melani Issue Date 30 December 2009 Issued To Management Representative Controlled Y N Copy

More information

Software Development for Medical Devices

Software Development for Medical Devices Software Development for Medical Devices Overcoming the Challenges of Compliance, Quality and Cost Software is fast becoming the differentiator for manufacturers of medical devices. The rewards of software

More information

BIG DATA KICK START. Troy Christensen December 2013

BIG DATA KICK START. Troy Christensen December 2013 BIG DATA KICK START Troy Christensen December 2013 Big Data Roadmap 1 Define the Target Operating Model 2 Develop Implementation Scope and Approach 3 Progress Key Data Management Capabilities 4 Transition

More information

Quality by Design Concept

Quality by Design Concept 3rd Jerusalem Conference on Quality and Pharma Sciences 6-7 June, 2012 QbD in Clinical Research - Where Can QbD Impact Clinical Research Practices? Dr. Yafit Stark Vice President, TEVA Pharmaceutical Industries,

More information

Complete Document & Process Management for Life Sciences on SharePoint 2010

Complete Document & Process Management for Life Sciences on SharePoint 2010 TM ComplianceSP TM on SharePoint 2010 Complete Document & Process Management for Life Sciences on SharePoint 2010 Overview With increasing pressure on costs and margins across Life Sciences, the Industry

More information

Compliance Control Procedure Execution Management System Reduces Compliance Risks by 10X

Compliance Control Procedure Execution Management System Reduces Compliance Risks by 10X Compliance Control Procedure Execution Management System Reduces Compliance Risks by 10X By John Helfrich, VelQuest Corporation INTRODUCTION The top drug GMP violations in 2009 involved failings in manufacturers'

More information

Risk Assessment Tools for Identifying Hazards and Evaluating Risks Associated with IVD Assays

Risk Assessment Tools for Identifying Hazards and Evaluating Risks Associated with IVD Assays Risk Assessment Tools for Identifying Hazards and Evaluating Risks Associated with IVD Assays Robert C. Menson, PhD AACC Annual Meeting Philadelphia, PA 22 July 2003 What Risks Must Be Managed? Risk to

More information

CAPA - the importance of data analysis

CAPA - the importance of data analysis CAPA - the importance of data analysis Presented by: Sue Jacobs QMS Consulting, Inc. 1 847 359 4456 sue@qmsconsultant.com QMS Consulting, Inc. 2007 1 Topics Regulatory Requirements Design Controls and

More information

Medical Product Development Certificate Program

Medical Product Development Certificate Program Life Sciences Medical Product Development Certificate Program Accelerate Your Career extension.uci.edu/mpd In today s competitive business environment, leaders are appointed based on credentials and experience.

More information

AssurX Makes Quality & Compliance a Given Not Just a Goal

AssurX Makes Quality & Compliance a Given Not Just a Goal AssurX Makes Quality & Compliance a Given Not Just a Goal TRACK. MANAGE. AUTOMATE. IMPROVE. AssurX s powerfully flexible software unites and coordinates information, activities and documentation in one

More information

Combination Products. Presented by: Karen S. Ginsbury For: IFF March 2014. PCI Pharma

Combination Products. Presented by: Karen S. Ginsbury For: IFF March 2014. PCI Pharma Combination Products Presented by: Karen S. Ginsbury For: IFF March 2014 Types of products Biological and medical device (freeze dried + syringe dual volume) Medical device and plasma devised product (syringe)

More information

Implementing New USP Chapters for Analytical Method Validation

Implementing New USP Chapters for Analytical Method Validation Implementing New USP Chapters for Analytical Method Validation March 2010 Ludwig Huber Fax.: +49 7243 602 501 E-mail: Ludwig_Huber@labcompliance.com Today s Agenda Handling Method Changes vs. Adjustments

More information